Divalproex Sodium Tablet, Delayed Release
Product Images NDC 60760-698

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 60760-698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

698-60 (Divalproex 60760 698 60)

Label for Divalproex Sodium Delayed-Release Tablets USP 250 mg. The label indicates a 60-count package of oral tablets, manufactured by Rising Health, LLC, East Brunswick, NJ, made in India. Packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label shows NDC 60760-698-60, with placeholder information for lot number and expiration date. Storage instructions specify controlled room temperature (15°-30°C).*

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar chart comparing the percentage effectiveness of placebo (PBO) versus divalproex sodium delayed-release tablets (DVPX) in two studies measuring YMRS and MRS outcomes. The chart shows higher percentages for DVPX in both studies, with values around 60% and 58% respectively, against 26% and 29% for placebo.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A line chart comparing percent reduction in CPS rate versus percent of patients for Divalproex Sodium delayed-release tablets and placebo. It shows the treatment group consistently achieving higher improvements compared to placebo across the patient population.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A line chart labeled Figure 3 showing the percent reduction in CRS rate on the vertical axis versus percent of patients on the horizontal axis. Two curves represent high dose (solid line) and low dose (dashed line) groups. The chart indicates improvement and worsening trends relative to no change.*

FDA Label Image

Figure 4 (Divalproex Fig4)

Bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and divalproex sodium delayed-release tablets across two studies. The vertical axis shows migraine rate frequency ranging from 0 to 6. In both studies, bars indicate lower migraine rates for divalproex sodium delayed-release tablets compared to placebo.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure of Divalproex Sodium showing its molecular composition with sodium ion and carbon chains represented in a polymeric form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.